Sign up Australia
Proactive Investors - Run By Investors For Investors

Valeant Pharmaceuticals sells Obagi skincare company in latest effort to cut debt

Valeant plans to use the proceeds from the sale of the business to reduce debt
skin
Valeant has been accused of hiking prices of drugs with little or no competition

Valeant Pharmaceuticals International Inc (NYSE:VRX) has agreed to sell its skincare business, Obagi Medical Products, to a Hong Kong-based firm for US$190mln in cash.

Obagi, a drug company that specialises in products for skin aging, skin damage and other skin probems, will be sold to Zhonghua Finance Acquisition Fund I LP.

Proceeds from the sale will be used to cut Valeant’s debt as the company works to turn around the business following a troubled year. The deal is expected to be completed in the second half.

Valeant sees Obagi generating a net profit of US$85mln and adjusted underlying earnings (EBITDA) of US$30mln.

Shares in Valeant shares 1.22% to US$17.44 in US pre-market trading.

Valeant has been trying to sell off its non-core assets to reduce its debt pile of about US$29bn as of 31 March in the wake of scandals over alleged fraud and price gouging. Last week the company said it paid down US$811mln of debt after selling its cancer treatment unit Dendreon Pharmaceuticals to China's Sanpower.

The drugmaker has received backlash for raising prices of old drugs with little or no competition but chief executive Joseph Papa has insisted that average price increase was lower than the consumer price index in 2016.

Last year former executives of Valeant and mail-order pharmacy Philidor were charged with running a fraud-and-kickback scheme that swindled Valeant out of millions.

 





Register here to be notified of future VRX Company articles
View full VRX profile View Profile

Valeant Pharmaceuticals Timeline

Related Articles

1507647205_biotech_517925923.jpg
October 11 2017
Last month the group revealed its Barocycler 2320EXTREME device had been selected as a finalist in the prestigious R&D 100 Awards for 2017.
picture of addict
Thu
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
diagram of the human microbiome
September 13 2017
OptiBiotix is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use